Skip to main content

RPRX

Stock
Health Care
Biotechnology

Performance overview

RPRX Price
Price Chart

Forward-looking statistics

Beta
0.34
Risk
24.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Company info

SectorHealth Care
IndustryBiotechnology
Employees90
Market cap$12.4B

Fundamentals

Enterprise value$24.8B
Revenue$2.3B
Revenue per employee—
Profit margin48.26%
Debt to equity77.82

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.45
Dividend per share$0.88
Revenue per share$5.09
Avg trading volume (30 day)$166M
Avg trading volume (10 day)$144M
Put-call ratio—

Macro factor sensitivity

Growth-0.6
Credit+1.4
Liquidity-0.7
Inflation-2.3
Commodities-0.2
Interest Rates-0.6

Valuation

Dividend yield2.44%
PEG Ratio8.28
Price to sales9.03
P/E Ratio8.28
Enterprise Value to Revenue10.96
Price to book2.31

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend dayMay 16, 2025

News

Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago.

Zacks Investment Research (May 8, 2025)
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga (November 6, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free